Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) - Total Liabilities
Based on the latest financial reports, Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) has total liabilities worth CN¥1.07 Billion CNY (≈ $157.14 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Zhejiang Anglikang Pharmaceutical Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Zhejiang Anglikang Pharmaceutical Co Ltd Class A - Total Liabilities Trend (2014–2025)
This chart illustrates how Zhejiang Anglikang Pharmaceutical Co Ltd Class A's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Zhejiang Anglikang Pharmaceutical Co Ltd balance sheet assets.
Zhejiang Anglikang Pharmaceutical Co Ltd Class A Competitors by Total Liabilities
The table below lists competitors of Zhejiang Anglikang Pharmaceutical Co Ltd Class A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
REVO INSURANCE SPA O.N.
F:H0O
|
Germany | €351.39 Million |
|
Once Upon a Farm, PBC
NYSE:OFRM
|
USA | $240.49 Million |
|
Chengdu Huaqi Houpu Holding Co Ltd
SHE:300471
|
China | CN¥990.69 Million |
|
Community West Bancshares
NASDAQ:CWBC
|
USA | $4.43 Billion |
|
Beijing Beilu Pharmaceutical
SHE:300016
|
China | CN¥852.80 Million |
|
J.S. Corrugating Machinery Co Ltd
SHE:000821
|
China | CN¥8.92 Billion |
|
Stratasys Ltd
NASDAQ:SSYS
|
USA | $230.86 Million |
|
Kvutzat Acro Ltd.
TA:ACRO
|
Israel | ILA4.96 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Zhejiang Anglikang Pharmaceutical Co Ltd Class A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 002940 net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Anglikang Pharmaceutical Co Ltd Class A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Anglikang Pharmaceutical Co Ltd Class A (2014–2025)
The table below shows the annual total liabilities of Zhejiang Anglikang Pharmaceutical Co Ltd Class A from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.08 Billion ≈ $158.56 Million |
-7.87% |
| 2024-12-31 | CN¥1.18 Billion ≈ $172.10 Million |
-0.98% |
| 2023-12-31 | CN¥1.19 Billion ≈ $173.80 Million |
+25.03% |
| 2022-12-31 | CN¥949.93 Million ≈ $139.00 Million |
+56.07% |
| 2021-12-31 | CN¥608.64 Million ≈ $89.06 Million |
+8.15% |
| 2020-12-31 | CN¥562.78 Million ≈ $82.35 Million |
+52.72% |
| 2019-12-31 | CN¥368.51 Million ≈ $53.92 Million |
-26.19% |
| 2018-12-31 | CN¥499.27 Million ≈ $73.06 Million |
-2.56% |
| 2017-12-31 | CN¥512.41 Million ≈ $74.98 Million |
+27.93% |
| 2016-12-31 | CN¥400.56 Million ≈ $58.61 Million |
-25.22% |
| 2015-12-31 | CN¥535.63 Million ≈ $78.38 Million |
+4.14% |
| 2014-12-31 | CN¥514.36 Million ≈ $75.27 Million |
-- |
About Zhejiang Anglikang Pharmaceutical Co Ltd Class A
Zhejiang AngLiKang Pharmaceutical CO.,LTD. engages in the research, development, production, and sale of pharmaceuticals in China and internationally. The company offers chemical raw materials for pharmaceuticals comprising oral cephalosporin antibiotic raw materials, including cephalexin, cefadroxil, cefaclor, and cefadroxil; alpha-keto acid raw materials; inhaled anesthetic raw materials, such … Read more